URO ONCO

Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

News Items

  • ESMO2014 update on Abiraterone

    Abiraterone and prednisone in men with CRPC prior to docetaxel earlier showed improved progression-free survival but follow up was too short to meet the co-primary endpoint of the COU-AA302 study: overall survival.

  • Cabozantinib fails to significantly prolong survival in men with metastatic Castration-Resistant Prostate Cancer

    Cabozantinib (XL184) is an oral tyrosine kinase inhibitor with activity against MET and vascular endothelial growth factor receptor 2. Although other VEGFR-targeting agents have failed in prostate cancer, expectations amongst oncologists were high that cabozantinib that also targets c-Met, critical in bone metastasis, would be a winning horse in metastatic castrate-resistant prostate cancer.

E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre

Subscribe

URO ONCO is made possible by an unrestricted educational grant from:

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.

The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views.